Suppr超能文献

[阴茎注射血管活性药物联合治疗452例勃起功能障碍患者的评估]

[Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].

作者信息

Segenreich E, Israilov S, Shmueli J, Simon D, Baniel J, Livne P

机构信息

Andrology Unit, Rabin Medical Center, Petah Tikva.

出版信息

Harefuah. 1998 May 1;134(9):673-8, 750.

Abstract

In the past 15 years there has been continuous increase in the use of injections into the corpora cavernosa of different vasoactive drugs for treatment of erectile dysfunction (ED). However, some of these drugs are very expensive, are not available everywhere, and have side effects. We therefore compared the success rate of the most widely used compounds, papaverine and regitine, in 452 patients (age range 26-85) with different types of ED. Each patient received in the clinic injections of papaverine, 6-25 mg, and regitine, 0.05-1.5 mg. When maximal rigidity of the penis (MRP) was > 80%, we instructed the patient to self-inject the drug at home, 5-30 minutes before coitus. If after 3 injections MRP was not > 80%, prostaglandin E1 (PGE1) in an average dose of 10-25 mcg was added. If there was no response, papaverin + regitine + PGE1 were given in higher dosage, and atropine sulfate, 0.02 + 0.06 mg, was added if necessary. Of 452 patients, 305 (67.4%) had MRP > 80% after 3 injections of papaverine plus regitine. The other patients received PGE1 in addition. This was helpful in 61 patients (41.5%), while 55 (63.9%) required papaverine + regitine + prostin in higher doses. Of these, only 31 received papaverine + regitine + PGE1 + atropine sulfate. Of these, 20 (64.5%) reached MRP > 80%, and 11 (2.4%) MRP < 60. For these 11 patients, we recommended a penile prosthesis. Thus in 67.4% of the 452 patients, papaverine + regitine injections were effective; in 41.5%, PGE1; in 63.9%, papaverine + regitine + prostin + atropine sulfate. Only 11 (2.4%) did not react to intracorporeal injection. This progressive method of treatment enabled us to select the optimal dosage and combinations of compounds in 441/452 patients (97.5%) according to the severity of their dysfunction. During follow-up of 6 months, spontaneous erections without injection were achieved in 115 (26.0%).

摘要

在过去15年里,向海绵体内注射不同血管活性药物治疗勃起功能障碍(ED)的应用持续增加。然而,其中一些药物非常昂贵,并非随处可得,且有副作用。因此,我们比较了最常用的药物罂粟碱和酚妥拉明在452例不同类型ED患者(年龄范围26 - 85岁)中的成功率。每位患者在诊所接受罂粟碱6 - 25毫克和酚妥拉明0.05 - 1.5毫克的注射。当阴茎最大硬度(MRP)> 80%时,我们指导患者在性交前5 - 30分钟在家自行注射药物。如果3次注射后MRP未> 80%,则添加平均剂量为10 - 25微克的前列腺素E1(PGE1)。如果没有反应,则给予更高剂量的罂粟碱 + 酚妥拉明 + PGE1,必要时添加0.02 + 0.06毫克硫酸阿托品。在452例患者中,305例(67.4%)在注射3次罂粟碱加酚妥拉明后MRP > 80%。其他患者另外接受了PGE1。这对61例患者(41.5%)有帮助,而55例(63.9%)需要更高剂量的罂粟碱 + 酚妥拉明 + 前列腺素。其中,只有31例接受了罂粟碱 + 酚妥拉明 + PGE1 + 硫酸阿托品。其中,20例(64.5%)达到MRP > 80%,11例(2.4%)MRP < 60。对于这11例患者,我们建议使用阴茎假体。因此,在452例患者中,67.4%的患者罂粟碱 + 酚妥拉明注射有效;41.5%的患者PGE1有效;63.9%的患者罂粟碱 + 酚妥拉明 + 前列腺素 + 硫酸阿托品有效。只有11例(2.4%)对海绵体内注射无反应。这种逐步治疗方法使我们能够根据441/452例患者(97.5%)功能障碍的严重程度选择最佳药物剂量和组合。在6个月的随访期间,115例(26.0%)患者在未注射的情况下实现了自发勃起。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验